J&J Licenses Hep B Treatments from Chia Tai Tianqing

In a rare move, Johnson & Johnson Innovation and Janssen Pharmaceuticals have in-licensed products from a Chinese drugmaker to develop drugs outside that country.

The deal with Chia Tai Tianqing Pharmaceutical Group gives J&J exclusive rights to develop, manufacture and commercialize undisclosed immune-modulating agents for a number of conditions — including chronic hepatitis B — outside China. Financial terms of the deal were not disclosed.